Combating COVID-19: Egypt To Receive The First Shipment Of Pfizer And AstraZeneca Coronavirus Drugs
The governments of the world are enforcing vaccinations to ensure the safety of the entire human population. Over the past few months, research for new medicines and vaccinations for the COVID-19 has intensified as the pandemic develops new strains. Moreover, health experts have warned that we will be confronting seasonal viruses in the upcoming months that could damage our immune system. Egypt is staying vigilant and ready for future waves.
Egypt is scheduled to get its first shipments of coronavirus medications from Pfizer and AstraZeneca in January, according to Egyptian health ministry spokesman Hossam Abdel-Ghaffar. In a statement, Abdel-Ghaffar has revealed that Egypt will receive Pfizer’s Paxlovid pills, which are needed to treat 20,000 coronavirus patients, as well as AstraZeneca’s Evusheld coronavirus antibody, which is needed to treat 50,000 patients, by the end of this month.
Abdel-Ghaffar reported that three Egyptian companies have finished producing Merck’s Molnupiravir coronavirus medication, which is used to keep COVID-19 patients out of the hospital.
In December, the US Food and Drug Administration (FDA) approved each of the three medications for emergency use. While Paxlovid and Molnupiravir are used to treat mild-to-moderate symptoms in the early stages of infection, Evusheld is used to prevent coronavirus infections.
Egypt has now fully vaccinated little more than 20% of its 102.8 million inhabitants in the last year, falling short of the World Health Organization’s global aim of fully vaccinating 40% of each country’s population by the end of 2021.
As time goes on, more vaccines and medications will become available, assisting us in surviving the epidemic and saving more lives. As a result, we must remain hopeful.